- Home
- KLRS vs RNXT Comparison
KLRS vs RNXT Comparison
Compare KLRS & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- RNXT
- Stock Information
- Founded
- KLRS 2019
- RNXT 2012
- Country
- KLRS United States
- RNXT United States
- Employees
- KLRS N/A
- RNXT N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- KLRS Health Care
- RNXT Health Care
- Exchange
- KLRS Nasdaq
- RNXT Nasdaq
- Market Cap
- KLRS 46.0M
- RNXT 44.6M
- IPO Year
- KLRS N/A
- RNXT 2021
- Fundamental
- Price
- KLRS $3.71
- RNXT $1.27
- Analyst Decision
- KLRS Strong Buy
- RNXT Strong Buy
- Analyst Count
- KLRS 2
- RNXT 2
- Target Price
- KLRS $23.00
- RNXT $7.50
- AVG Volume (30 Days)
- KLRS 689.3K
- RNXT 579.5K
- Earning Date
- KLRS 11-15-2025
- RNXT 11-12-2025
- Dividend Yield
- KLRS N/A
- RNXT N/A
- EPS Growth
- KLRS N/A
- RNXT N/A
- EPS
- KLRS N/A
- RNXT N/A
- Revenue
- KLRS N/A
- RNXT $662,000.00
- Revenue This Year
- KLRS N/A
- RNXT $2,988.37
- Revenue Next Year
- KLRS N/A
- RNXT $300.60
- P/E Ratio
- KLRS N/A
- RNXT N/A
- Revenue Growth
- KLRS N/A
- RNXT N/A
- 52 Week Low
- KLRS $2.14
- RNXT $0.75
- 52 Week High
- KLRS $24.15
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- KLRS 52.79
- RNXT 60.58
- Support Level
- KLRS $2.37
- RNXT $1.06
- Resistance Level
- KLRS $4.90
- RNXT $1.45
- Average True Range (ATR)
- KLRS 0.70
- RNXT 0.11
- MACD
- KLRS -0.02
- RNXT 0.03
- Stochastic Oscillator
- KLRS 24.95
- RNXT 67.27
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.